A large majority of creditors and shareholders have voted in favor of the draft safeguard plan
This plan includes a 70% reduction in debt, from €40 million to €12 million, with a payment schedule over 10 years and a fundraising of at least €5 million.
Webinar for shareholders and investors
Monday, October 6, 2025, at 6:00 PM CEST
Paris and Boston, October 6, 2025 – 08h00 CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced the results of the vote by the classes of affected parties, including shareholders, holders of securities giving access to capital, and creditors of Mauna Kea Technologies, on the draft safeguard plan.
A majority of the classes of affected parties voted in favor of the draft safeguard plan, and the voting results allow the Company to request the Paris Commercial Court (the “Court”) to approve its draft safeguard plan.
Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, commented: “This is a key milestone we have reached today. The favorable vote from a majority of the affected parties demonstrates their confidence in our vision and our outlook. I want to sincerely thank them. The next step is the presentation of the draft safeguard plan to the Court, including the debt reduction as voted and the refinancing of the Company. On this second point, the prospect of a healthier financial structure, coupled with the reduction of our operating loss and our commercial momentum in the US, has allowed us to have very positive discussions with numerous investors. We are now very confident in our ability to raise the necessary funds to support the company’s commercial development until it reaches profitability.”
